Unknown

Dataset Information

0

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.


ABSTRACT: The majority of low-grade and secondary high-grade gliomas carry heterozygous hotspot mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or the mitochondrial variant IDH2. These mutations mostly involve Arg132 in IDH1, and Arg172 or Arg140 in IDH2. Whereas IDHs convert isocitrate to alpha-ketoglutarate (?-KG) with simultaneous reduction of NADP(+) to NADPH, these IDH mutants reduce ?-KG to D-2-hydroxyglutarate (D-2-HG) while oxidizing NADPH. D-2-HG is a proposed oncometabolite, acting via competitive inhibition of ?-KG-dependent enzymes that are involved in metabolism and epigenetic regulation. However, much less is known about the implications of the metabolic stress, imposed by decreased ?-KG and NADPH production, for tumor biology. We here present a novel heterozygous IDH1 mutation, IDH1(R314C), which was identified by targeted next generation sequencing of a high grade glioma from which a mouse xenograft model and a cell line were generated. IDH1(R314C) lacks isocitrate-to-?-KG conversion activity due to reduced affinity for NADP(+), and differs from the IDH1(R132) mutants in that it does not produce D-2-HG. Because IDH1(R314C) is defective in producing ?-KG and NADPH, without concomitant production of the D-2-HG, it represents a valuable tool to study the effects of IDH1-dysfunction on cellular metabolism in the absence of this oncometabolite.

SUBMITTER: van Lith SA 

PROVIDER: S-EPMC4962051 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


The majority of low-grade and secondary high-grade gliomas carry heterozygous hotspot mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or the mitochondrial variant IDH2. These mutations mostly involve Arg132 in IDH1, and Arg172 or Arg140 in IDH2. Whereas IDHs convert isocitrate to alpha-ketoglutarate (α-KG) with simultaneous reduction of NADP(+) to NADPH, these IDH mutants reduce α-KG to D-2-hydroxyglutarate (D-2-HG) while oxidizing NADPH. D-2-HG is a proposed oncometabolite, acting via  ...[more]

Similar Datasets

| S-EPMC5217781 | biostudies-literature
| S-EPMC2838977 | biostudies-literature
| S-EPMC5193019 | biostudies-literature
| S-EPMC8418478 | biostudies-literature
| S-EPMC7076064 | biostudies-literature
| S-EPMC4308293 | biostudies-literature
| S-EPMC7586285 | biostudies-literature
| S-EPMC4482584 | biostudies-literature
| S-EPMC8488436 | biostudies-literature
| S-EPMC9825307 | biostudies-literature